Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension

Guthrie, Robert; Saini, R.P.; Herman, Theodore S.; Pleskow, Warren W.; Sprecher, Dennis L.; Collins, Gregory T.

doi:10.2165/00044011-199815030-00006

Cited by 25 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 It is approved for the treatment of hypertensive adults at once-daily doses of 75 mg, 150 mg, and 300 mg. 13 In hypertensive adults, once-daily administration of irbesartan effectively lowers blood pressure (BP) in a dose-dependent manner across the approved dosage range, [14][15][16] with placebolike tolerability demonstrated at doses up to 900 mg. 8 In healthy subjects, irbesartan is rapidly and almost completely absorbed after oral administration, with a mean absolute bioavailability of 60% to 80%. 17 Mean total body clearance is 157 to 176 mL/min, of which 3 mL/min is renal clearance.…”

mentioning

confidence: 99%

The Pharmacokinetics of Irbesartan in Hypertensive Children and Adolescents

Şakarcan

Tenney

Wilson

et al. 2001

The Journal of Clinical Pharma

View full text Add to dashboard Cite

An open-label study was conducted to characterize the pharmacokinetics and antihypertensive response to irbesartan in children (1-12 years) and adolescents (13-16 years) with hypertension. Patients received single once-daily oral doses of irbesartan 2 mg/kg (maximum of 150 mg once daily) for 2 to 4 weeks (+/- nifedipine or hydrochlorothiazide). Plasma irbesartan concentrations were determined by a validated high-performance liquid chromatography/fluorescence method from blood samples taken predose, up to 24 hours after dosing on Day 1, and up to 48 hours after the final dose. The plasma concentration-time profiles were similar between the 6- to 12-year and the 13- to 16-year age groups and to that previously determined from a study of adult subjects receiving approximately 2 mg/kg (i.e., 150 mg) oral irbesartan once daily. Mean reductions in systolic/diastolic blood pressure were 16/10 mmHg at Day 28 with irbesartan monotherapy (n = 8). Irbesartan was well tolerated and may be a treatment option for pediatric hypertensive patients.

show abstract

mentioning

confidence: 99%

The Pharmacokinetics of Irbesartan in Hypertensive Children and Adolescents

Şakarcan

Tenney

Wilson

et al. 2001

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Placebo-controlled studies with irbesartan (75-300 mg one per day) have shown a statistically significant BP reduction for both systolic and diastolic BP values in mild-to-moderate hypertensive patients [14][15][16]. BP lowering effect has a linear relationship with the dose up to 300 mg/day where a ceiling effect occurs, and no further BP decrease is observed with further dose increments [17].…”

Section: Hypertensionmentioning

confidence: 99%

The cost–effectiveness of irbesartan for hypertension

Borghi

Urso

Cicero

2015

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

High blood pressure is a very common problem in the adult and elderly population, both in developed and developing countries. A relatively large number of drug classes are available to treat this condition and prevent its complications, which are not only more frequent in the aforementioned patients but also those affected by metabolic syndrome and/or Type 2 diabetes. Irbesartan is an angiotensin-receptor blocker class drug with good antihypertensive efficacy and specific pharmacological characteristics, whose efficacy has been more deeply evaluated in metabolically complex hypertensive patients. In this review, the authors will analyze its effectiveness in preventing or delaying organ damage in hypertensive patients, with a closer look at the economic implications of treating hypertension with irbesartan in the context of available antihypertensive drugs.

show abstract

“…The ability of irbesartan to produce dose-related reductions in BP was further confirmed in 2 double-blind, randomized, placebo-controlled trials. In a dose-titration study (11), 319 patients received irbesartan 75 mg, 150 mg, or placebo once daily; after 6 weeks, doses were doubled for those patients in whom SeDBP was ³ 90 mm Hg. As seen in the dose-ranging studies, statistically significant reductions in BP over placebo occurred with irbesartan 75 mg/150 mg and 150 mg/300 mg as early as 2 weeks, the first scheduled clinic visit.…”

Section: Previous Partmentioning

confidence: 99%

A Review of the Clinical Experience with the Angiotensin II Receptor Antagonist Irbesartan

Waeber

2000

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension

Cited by 25 publications

References 17 publications

The Pharmacokinetics of Irbesartan in Hypertensive Children and Adolescents

The Pharmacokinetics of Irbesartan in Hypertensive Children and Adolescents

The cost–effectiveness of irbesartan for hypertension

A Review of the Clinical Experience with the Angiotensin II Receptor Antagonist Irbesartan

Contact Info

Product

Resources

About